Pediatric Gastroenterology, Hepatology & Nutrition

The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition (대한소아소화기영양학회)
권호 표지
DOI QR코드

DOI QR Code

Current Role of Lamivudine Regarding Therapeutic Response and Resistance in Children with Chronic Hepatitis B

  • Hong, Suk Jin (Department of Pediatrics, Kyungpook National University School of Medicine) ;
  • Kim, Yeo Hyang (Department of Pediatrics, Kyungpook National University School of Medicine) ;
  • Choe, Byung-Ho (Department of Pediatrics, Kyungpook National University School of Medicine) ;
  • Park, Hyo Jung (Department of Pediatrics, Kyungpook National University School of Medicine) ;
  • Tak, Won-Young (Department of Internal Medicine, Kyungpook National University School of Medicine) ;
  • Kweon, Young-Oh (Department of Internal Medicine, Kyungpook National University School of Medicine)
  • Received : 2013.03.18
  • Accepted : 2013.06.17
  • Published : 2013.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To identify the predictive factors of long-term therapeutic response or resistance to lamivudine treatment in children and adolescents with chronic hepatitis B. Methods: Eighty one children and adolescents with chronic hepatitis B were included, who received lamivudine treatment for at least 6 months. Their condition was monitored for at least 12 months (12-88 months) thereafter. Twenty one (25.9%) were preschool children ($age{\leq}6$). For patients who had developed HBeAg seroconversion or breakthrough, univariate and multivariate analyses were used to identify the effects of age, gender, pretreatment alanine aminotransferase (ALT) and hepatitis B virus DNA levels. Results: HBeAg seroconversion occurred in 49 (60.5%) of the 81 patients after the initiation of the lamivudine therapy. In 65 patients whom were monitored for over 24 months, the seroconversion rate was significantly higher in younger patients (p=0.040), especially in those patients of preschool age ($age{\leq}6$, p=0.031). The seroconversion rate was significantly higher in higher pretreatment ALT (p=0.003). The breakthrough occurred in 21 (25.9%) of the 81. The breakthrough rate was lower in younger aged patients ($age{\leq}6$), and with higher pretreatment ALT levels, but no significant difference. Conclusion: Younger age is a good predictor of HBeAg seroconversion in children with long-term lamivudine treatment as well as high pretreatment ALT levels.

Keywords

References

  1. Bortolotti F, Cadrobbi P, Crivellaro C, Guido M, Rugge M, Noventa F, et al. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology 1990;99:805-10. https://doi.org/10.1016/0016-5085(90)90972-4
  2. Conjeevaram HS, Di Bisceglie AM. Management of chronic viral hepatitis in children. J Pediatr Gastroenterol Nutr 1995;20:365-75. https://doi.org/10.1097/00005176-199505000-00001
  3. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63. https://doi.org/10.1056/NEJM199910213411702
  4. Choe BH, Lee JH, Jang YC, Jang CH, Oh KW, Kwon S, et al. Long-term therapeutic efficacy of lamivudine compared with interferon-alpha in children with chronic hepatitis B: the younger the better. J Pediatr Gastroenterol Nutr 2007;44:92-8. https://doi.org/10.1097/01.mpg.0000243439.47334.4e
  5. Hom X, Little NR, Gardner SD, Jonas MM. Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection. Pediatr Infect Dis J 2004;23:441-5. https://doi.org/10.1097/01.inf.0000126412.93562.f5
  6. Liberek A, Szaflarska-Poplawska A, Korzon M, Luczak G, Gora-Gebka M, Los-Rycharska E, et al. Lamivudine therapy for children with chronic hepatitis B. World J Gastroenterol 2006;12:2412-6. https://doi.org/10.3748/wjg.v12.i15.2412
  7. Park NH, Shin JW, Park JH, Bang SJ, Kim DY, Joo KR, et al. Predictive factors and efficacy of lamivudine treatment in chronic hepatitis B infection. Korean J Gastroenterol 2003;42:303-12.
  8. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al; Asia Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32. https://doi.org/10.1053/jhep.2001.25084
  9. Yoon SK, Jang JW, Kim CW, Bae SH, Choi JY, Choi SW, et al. Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion. Intervirology 2005;48:341-9. https://doi.org/10.1159/000086061
  10. Hartman C, Berkowitz D, Eshach-Adiv O, Hino B, Rimon N, Satinger I, et al. Long-term lamivudine therapy for chronic hepatitis B infection in children unresponsive to interferon. J Pediatr Gastroenterol Nutr 2006;43:494-8. https://doi.org/10.1097/01.mpg.0000235982.34323.67
  11. Sokal EM, Kelly DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, et al. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology 2006;43:225-32. https://doi.org/10.1002/hep.21020
  12. Jonas MM, Mizerski J, Badia IB, Areias JA, Schwarz KB, Little NR, et al; International Pediatric Lamivudine Investigator Group. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-13. https://doi.org/10.1056/NEJMoa012452
  13. Sokal EM, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM, Goyens P, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998; 114:988-95. https://doi.org/10.1016/S0016-5085(98)70318-X
  14. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32:828-34. https://doi.org/10.1053/jhep.2000.17912
  15. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-6. https://doi.org/10.1053/jhep.2000.16665
  16. Hong SP, Han KH, Ahn SH, Paik YH, Moon BS, Chon CY, et al. Long-term efficacy and durability of lamivudine therapy in patients with chronic hepatitis B. Korean J Hepatol 2001;7:423-31.
  17. Broderick A, Jonas MM. Management of hepatitis B in children. Clin Liver Dis 2004;8:387-401. https://doi.org/10.1016/j.cld.2004.02.007
  18. Kim JM, Choe BH, Chu MA, Cho SM. Comparison of lamivudine-induced HBsAg loss rate according to age in children with chronic hepatitis B. Korean J Hepatol 2009;15:168-78. https://doi.org/10.3350/kjhep.2009.15.2.168
  19. Figlerowicz M, Kowala-Piaskowska A, Filipowicz M, Bujnowska A, Mozer-Lisewska I, Słuzewski W. Efficacy of lamivudine in the treatment of children with chronic hepatitis B. Hepatol Res 2005;31:217-22. https://doi.org/10.1016/j.hepres.2005.02.003
  20. Dikici B, Ozgenc F, Kalayci AG, Targan S, Ozkan T, Selimoglu A, et al. Current therapeutic approaches in childhood chronic hepatitis B infection: a multicenter study. J Gastroenterol Hepatol 2004;19:127-33. https://doi.org/10.1111/j.1440-1746.2004.03209.x
  21. Dikici B, Ece A, Bosnak M. Which combination should be preferred in the management of children with chronic hepatitis B infection? J Clin Gastroenterol 2005;39:745-6. https://doi.org/10.1097/01.mcg.0000173934.46654.1e
  22. Ozgenc F, Arikan C, Sertoz RY, Nart D, Aydogdu S, Yagci RV. Effect of long-term lamivudine in chronic hepatitis B virus-infected children. Antivir Ther 2004;9:729-32.
  23. Choe BH, Kim JM, Lee JH, Jang YC, Jang CH, Oh KW, et al. Lamivudine treatment in children with chronic hepatitis B: long-term therapeutic Response, optimal duration and resistance. the 39th Annual Meeting of ESPGHAN; 2006; Dresden, Germany. J Pediatr Gastroenterol Nutr 2006:E64-5.
  24. Hong SJ, Choe BH. Strategy to overcome drug resistance that develops during treatment of chronic hepatitis b in children. Pediatr Gastroenterol Hepatol Nutr 2012;15:63-73. https://doi.org/10.5223/pghn.2012.15.2.63
  25. Chu M, Cho SM, Choe BH, Cho MH, Kwon S, Lee WK. Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B. J Pediatr Gastroenterol Nutr 2012;55:648-52. https://doi.org/10.1097/MPG.0b013e318262a737

Cited by

  1. A disappearing vertical infection: will hepatitis B be a forgotten disease in children? vol.29, pp.3, 2014, https://doi.org/10.3904/kjim.2014.29.3.296
  2. Lamivudine resistance in children with chronic hepatitis B vol.7, pp.6, 2013, https://doi.org/10.4254/wjh.v7.i6.896
  3. Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B vol.33, pp.2, 2013, https://doi.org/10.3346/jkms.2018.33.e11
  4. A Multicenter Study of the Antiviral Efficacy of Entecavir Monotherapy Compared to Lamivudine Monotherapy in Children with Nucleos(t)ide-naïve Chronic Hepatitis B vol.33, pp.8, 2013, https://doi.org/10.3346/jkms.2018.33.e63
  5. 만성 B형 간염 소아청소년 환자에서의 라미부딘 치료 효과 vol.25, pp.2, 2013, https://doi.org/10.14776/piv.2018.25.e2